Print

Lundbeck Inc. (LUN.CO) Announces Positive Results for Brintellix™ (Vortioxetine) in Adult Patients With Major Depression and Inadequate Response to SSRI or SNRI Therapy  
4/8/2013 11:37:26 AM

Valby, Denmark, 8 April 2013 - H. Lundbeck A/S (Lundbeck) today announced positive results for the REVIVE study, a double-blind randomized study of Brintellix™ (vortioxetine) versus agomelatine in adults with major depression (MDD) who changed antidepressant treatment after an inadequate response to SSRI or SNRI treatment. In this study, the objective was to compare the efficacy and tolerability of flexible dose treatment with Brintellix (10-20mg/day) versus agomelatine (25-50 mg/day) in this challenging MDD patient population. The study was conducted in Europe and one of the newest antidepressants agomelatine was chosen as a comparator because of its different mode of action from conventional SSRI/SNRI therapies.
//-->